Skip to main content

Table 1 Patient baseline characteristics

From: Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

  Planned dose level, mg/m2  
  1.5 3 6 8.4 10 12 Total
  (n = 1) (n = 1) (n = 4) (n = 12) (n = 7) (n = 6) (N = 31)
Age, years, median (range) 48 52 44 55 51
(67–67) (36–36) (39–51) (35–69) (31–65) (34–70) (31–70)
Male, n (%) 1 (100) 0 1 (25.0) 2 (16.7) 3 (42.9) 2 (33.3) 9 (29.0)
Caucasian, n (%) 1 (100) 1 (100) 4 (100) 12 (100) 7 (100) 6 (100) 31 (100)
ECOG performance status, n (%)        
  0 1 (100) 1 (25.0) 2 (16.7) 4 (57.1) 4 (66.7) 12 (38.7)
  1 3 (75.0) 9 (75.0) 2 (28.6) 2 (33.3) 16 (51.6)
  2 1 (100) 1 (8.3) 1 (14.3) 3 (9.7)
Tumour type, n (%)        
  Breast NA NA NA NA NA NA 13 (41.9)
  Ovary NA NA NA NA NA NA 3 (9.7)
  Stomach NA NA NA NA NA NA 3 (9.7)
  Small bowel NA NA NA NA NA NA 2 (6.5)
  Other NA NA NA NA NA NA 10 (32.3)
Prior anticancer therapy, n (%)        
  Chemotherapy only 1 (8.3) 1 (3.2)
  Immunotherapy* 1 (14.3) 1 (3.2)
  Surgery only 1 (100) 1 (3.2)
  Combination therapy 1 (100) 4 (100) 11 (91.7) 6 (85.7) 6 (100) 28 (90.3)
  1. * Immunotherapy + biological markers. NA not available.